Shyama Sidique

Shyama Sidique has worked in the field of biochemistry for over a decade. In 2022, they began working as a Principal Scientist for 858 Therapeutics. From 2012 to 2022, they were a Senior Research Scientist at ActivX Biosciences. From 2007 to 2012, they were a Post Doctoral Associate at Sanford-Burnham Medical Research Institute, where they were part of a multidisciplinary team that followed up on hits from the NIH's Molecular Library Production Center Network (MLPCN). Shyama also led chemistry efforts in various drug discovery projects and developed SAR and designed and synthesized several potent chemical probes which inhibit the activity of Tissue non specific alkaline phosphatase (TNAP) in vitro. Additionally, they designed and synthesized stable and selective allosteric inhibitors of NS2B-NS3 protease as a potential therapeutic for West Nile Virus.

Shyama Sidique received their PhD in Organic Chemistry from Wayne State University in 2007, and their BSc in Chemistry from the University of Peradeniya in 2000.